Zacks Research Has Positive Forecast for JAZZ Q2 Earnings

Key Points

• Zacks Research has raised its Q2 2027 earnings estimate for Jazz Pharmaceuticals to $5.10 per share, up from the previous estimate of $4.74.
• The company reported a Q2 loss of ($8.25) EPS, missing the consensus estimate by ($2.64) despite revenues meeting expectations at $1.05 billion.
• Jazz Pharmaceuticals has received a mix of ratings from analysts, with fourteen holding "Buy" ratings and a price target range varying from $151.00 to $202.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Equities researchers at Zacks Research lifted their Q2 2027 earnings estimates for Jazz Pharmaceuticals in a note issued to investors on Thursday, October 9th. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will earn $5.10 per share for the quarter, up from their previous estimate of $4.74. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.

Several other research firms also recently commented on JAZZ. The Goldman Sachs Group raised their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research note on Friday, August 29th. Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a report on Wednesday. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Royal Bank Of Canada increased their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $178.93.

Jazz Pharmaceuticals Trading Up 0.3%

JAZZ stock opened at $138.15 on Friday. The company has a market capitalization of $8.38 billion, a PE ratio of -20.53, a P/E/G ratio of 8.46 and a beta of 0.28. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06. The firm's 50-day moving average is $125.48 and its 200 day moving average is $115.76. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 3.6% in the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company's stock worth $271,003,000 after purchasing an additional 87,576 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after buying an additional 293,360 shares during the last quarter. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after buying an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. raised its position in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company's stock worth $182,664,000 after buying an additional 59,252 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its position in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after buying an additional 391,660 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.